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Mutations in COX7B Cause Microphthalmia with Linear
Skin Lesions, an Unconventional Mitochondrial Disease
Alessia Indrieri,1 Vanessa Alexandra van Rahden,2 Valeria Tiranti,3 Manuela Morleo,1 Daniela Iaconis,1
Roberta Tammaro,1 Ilaria D’Amato,3 Ivan Conte,1 Isabelle Maystadt,4 Stephanie Demuth,5
Alex Zvulunov,6 Kerstin Kutsche,2 Massimo Zeviani,3 and Brunella Franco1,7,*
Microphthalmia with linear skin lesions (MLS) is an X-linked dominant male-lethal disorder associated with mutations in holocyto-
chrome c-type synthase (HCCS), which encodes a crucial player of the mitochondrial respiratory chain (MRC). Unlike other mitochon-
drial diseases, MLS is characterized by a well-recognizable neurodevelopmental phenotype. Interestingly, not all clinically diagnosed
MLS cases have mutations inHCCS, thus suggesting genetic heterogeneity for this disorder. Among the possible candidates, we analyzed
the X-linked COX7B and found deleterious de novomutations in two simplex cases and a nonsensemutation, which segregates with the
disease, in a familial case. COX7B encodes a poorly characterized structural subunit of cytochrome c oxidase (COX), the MRC complex
IV. We demonstrated that COX7B is indispensable for COX assembly, COX activity, and mitochondrial respiration. Downregulation
of the COX7B ortholog (cox7B) in medaka (Oryzias latipes) resulted in microcephaly and microphthalmia that recapitulated the MLS
phenotype and demonstrated an essential function of complex IV activity in vertebrate CNS development. Our results indicate an
evolutionary conserved role of theMRC complexes III and IV for the proper development of the CNS in vertebrates and uncover a group
of mitochondrial diseases hallmarked by a developmental phenotype.Mitochondria are key players in crucial cellular functions
that include oxidative metabolism, ion homeostasis, signal
transduction, and programmed cell death. When dysfunc-
tional, mitochondria can contribute to the pathogenesis
of a variety of human diseases, such as cancer, neurodegen-
eration, and aging.1,2
Mitochondrial disorders are associated with abnormali-
ties of the common final pathway of mitochondrial energy
metabolism, i.e., oxidative phosphorylation (OXPHOS).
Their clinical manifestations are extremely heterogeneous
and range from lesions of single tissues or structures, such
as the optic nerve in Leber’s hereditary optic neuropathy
(LHON [MIM 535000) or the cochlea in maternally
inherited nonsyndromic deafness (MIM 50008), to more
widespread lesions, includingmyopathies, encephalomyo-
pathies, cardiopathies, or complex multisystem syn-
dromes. The age of onset for these diseases ranges from
neonatal to adult life.3,4
Microphthalmia with linear skin lesions (MLS [MIM
309801]) is an X-linked dominant male-lethal neurodeve-
lopmental disorder due to mutations in holocytochrome
c-type synthase (HCCS [MIM 30056]).5 Impaired HCCS
function in yeast andmice results in OXPHOS defects, sup-
porting a crucial role for HCCS in the formation and func-
tion of the mitochondrial respiratory chain (MRC).6,7
MLS-affected females exhibit microphthalmia and
distinctive linear skin defects usually limited to the face
and neck with areas of aplastic skin, which heals to form
hyperpigmented lesions. Additional features include facial1Telethon Institute of Genetics and Medicine, 80131 Naples, Italy; 2Institu
Hamburg, Germany; 3Unit of Molecular Neurogenetics, The Foundation ‘‘Car
Humaine, Institut de Pathologie et de Genetique, 6041 Gosselies (Charleroi), B
6Schneider Children’s Medical Center of Israel, Faculty of Health Sciences, Me
84105 Beer-Sheva, Israel; 7Medical Genetics Services, Department of Pediatric
*Correspondence: franco@tigem.it
http://dx.doi.org/10.1016/j.ajhg.2012.09.016. 2012 by The American Societ
942 The American Journal of Human Genetics 91, 942–949, Novembdysmorphisms, sclerocornea, corneal opacities, agenesis of
the corpus callosum, ventriculomegaly, microcephaly,
intellectual disability, infantile seizures, and cardiac anom-
alies. The clinical manifestations vary among affected indi-
viduals. Although most of the affected females present
with the classical phenotype, a significant number display
only a subset of features: some show the typical skin
defects without ocular abnormalities, and others display
eye abnormalities without skin defects8 (also see GeneRe-
views in Web Resources). The majority of affected indi-
viduals display monosomy of the Xp22.3 region, where
HCCS is located. Interestingly, there is no correlation
between the phenotype and the extent of the deletion.9
Several authors have suggested that tissue-specific differen-
tially skewed inactivation of the X chromosome could
play a critical role in the development of MLS (reviewed
in Van den Veyver,10 Franco and Ballabio,11 and Morleo
and Franco12), in the intrafamilial variability, and in the
clinical differences observed among simplex cases. An
example of intrafamilial variability is represented by an
affected female who only presented with the typical skin
defects and who had an affected female fetus with anen-
cephaly. The cytogenetic analyses revealed that both
mother and fetus had the same Xp22 deletion, one of
the largest described to date for MLS.9
The salient features of MLS differ from those found in
‘‘canonical’’ mitochondrial diseases that are usually char-
acterized by postnatal organ failure rather than impaired
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Figure 1. Photographs of Individuals in whom COX7B Mutations Were Identified
(A and B) Photographs of case 2 at the ages of 1 year and 10 months (A) and 7 years (B). She had an asymmetric face with limited eyelid
closure and linear skin defects (which became less obvious with age) on the face and neck.
(C) Pedigree of family 1. Proband II.4 is the fourth child of healthy and unrelated parents. The couple has three healthy daughters, II.1,
II.2, and II.3, and one healthy son, II.5. Three pregnancies ended with spontaneous abortions of unknown sex early in the first trimester.
(D–H) Photographs of individual II.4 (F–H) and her mother (I.2). At birth, individual I.2 presented with linear skin defects, which healed
with scaring (arrows in D and E). Individual II.4 had facial dysmorphism with telecanthus, long upslanting palpebral fissures, a short
nose, mild retrognathia, and posteriorly rotated ears (G). Linear and patchy erythroderma is located on the cheeks and neck; it was
more pronounced at birth (F) than at the age of 5 years (H).represents a remarkable example of a truly developmental
phenotype associated with mitochondrial dysfunction.
Moreover, the skin involvement in mitochondrial diseases
is atypical and can include hirsutism and hypertrichosis as
described in Leigh syndrome (MIM 256000) and twisted
hairs as reported in Bjornstad syndrome (MIM 262000).13
HCCS is highly conserved throughout evolution from
fungi to metazoan and catalyzes the incorporation of
heme moieties on both cytochrome (Cyt) c1, an integral
component of MRC complex (C) III, and Cytc, the mito-
chondrial CIII–CIV electron shuttle.14,15 A few clinically
diagnosedMLS cases inwhomnomutations inHCCS could
be found have been identified16,17 (B.F. and K.K., unpub-
lished results), thus suggesting genetic heterogeneity for
this disorder. In all these cases, analysis of the methylation
pattern revealed 100% skewing of X chromosome inactiva-
tion in peripheral-blood cells (data not shown).
We postulated that mutations affecting other compo-
nents of CIII–CIV could lead to the MLS phenotype. Cyto-
chrome c oxidase (COX), a fundamental MRC complex
(CIV), in humans comprises three mitochondrial-encoded
proteins (COX1, COX2, and COX3) that assemble with
ten nuclear-encoded proteins (COX4, COX5A, COX5B,
COX6A, COX6B, COX6C, COX7A, COX7B, COX7C, and
COX8) to form the mature holocomplex.18–21 Because of
the expected X-linked inheritance pattern, we selected,
among possible candidates, the only X-linked gene,
COX7B (MIM 603792), which encodes a small and poorly
characterized subunit of CIV.22,23 We then analyzed 14
available MLS-affected females in whom mutationalThe Americananalysis failed to detect mutations in HCCS, and we found
three mutations in COX7B.
Case 1 is the first child of unrelated Jewish parents. She
was born at term and displayed linear skin lesions on the
neck and face at birth. Her mother had had two previous
spontaneous abortions of unknown sex during the first
trimesterofpregnancy.This individualpresentedwith facial
dysmorphisms, short stature, microcephaly, and poor
growth. Eye examination was normal and showed neither
microphthalmia nor visual impairment. Her psychomotor
development was normal. A full description of this case is
available.24 Fluorescent in situ hybridization (FISH) studies
excluded deletion and translocation of the Xp22 region.
Case 2 was born at term from nonconsanguineous
parents. She presented with poor growth, microcephaly,
multiple linear skin defects on the face and neck, an asym-
metric face with limited eyelid closure, a small chin, and a
right clumped foot. A right diaphragmatic hernia was
surgically corrected. A cranial ultrasound revealed a thin
corpus callosum. No ocular abnormalities were detected.
An echocardiogram showed ventricular hypertrophy,
pulmonary hypertension, and a small atrial septal defect.
She also had left renal agenesis and ureteral duplication
of the right kidney. During a follow-up examination, she
showed short stature. Linear skin defects healed over
time, although they were still evident on the cheeks and
chin (Figures 1A and 1B). She had mild psychomotor
delay and learning difficulties. Routine cytogenetic anal-
ysis revealed a normal female karyotype. FISH studies
excluded deletion and translocation of the Xp22 region.Journal of Human Genetics 91, 942–949, November 2, 2012 943
Figure 2. COX7B Mutations in Individuals with MLS
(A) Sequence electropherograms from genomic DNA of case 1. She was found to be heterozygous for a de novo 1 bp deletion (leading to
a frameshift) in exon 3 of COX7B.
(B) Sequence electropherograms from genomic DNA of case 2. She was found to be heterozygous for a de novo splice site mutation, c.41-
2A>G, in intron 1.
(C) Sequence electropherograms from genomic DNA of individual II.4 from family 1. The heterozygous mutation c.55C>T (p.Gln19*) in
exon 2 was found in individuals II.4 and I.2.
(D) Sequence electropherograms of COX7B transcripts obtained from a minigene assay. Representative sequences of a transcript
(containing the spliced exon 2 of COX7B) obtained from the WT construct is shown on the top, whereas one representative transcript
obtained from the minigene with the c.41-2A>G mutation is shown on the bottom. Mutant (c.41-2G) COX7B transcripts result in a
truncated COX7B (p.Val14Glyfs*19). Nucleotide triplets and encoded amino acids are indicated.In family 1, proband II.4 is the fourth child of unrelated
individuals. Before she was born, her mother, individual
I.2, had three pregnancies that ended with spontaneous
abortions of unknown sex within the first trimester
(Figure 1C). At birth, individual I.2 presented with linear
skin defects, which became less obvious with age (Figures
1D and 1E). She has mild myopia and normal cognitive
functions. Proband II.4 was born at 30 weeks of gestation
with a normal birth weight and microcephaly. She pre-
sented with linear and patchy erythroderma (more evident
at birth) on the cheeks and neck (Figures 1F and 1H), facial
dysmorphisms (including telecanthus, arched eyebrows,
long upslanting palpebral fissures, a short nose, mild retro-
gnathia, and posteriorly rotated ears) (Figure 1G), and
tetralogy of Fallot. She also had an asymmetric thorax
withwidely spacednipples, bilateral clinodactylyof thefifth
fingers, andabilateral sandalgap. Shedeveloped intellectual
disabilities andwas diagnosedwith attention-deficit/hyper-
activity disorder at 4 years of age. When she was 3 months
old, brain magnetic resonance imaging showed delayed944 The American Journal of Human Genetics 91, 942–949, Novembmyelination. She had poor vision, and an ophthalmologic
examination revealed pale optic discs and altered visual-
evoked potentials. Array-comparative-genomic-hybridiza-
tion analysis (Agilent 44K) in II.4 revealed a 387 kb micro-
duplication of unknown clinical significance on 12p13.33
and excluded a deletion of the Xp22 region. This micro-
duplication was also present in her healthy father.
Individuals enrolled in this study were collected under
the approval of the ethics committee responsible for each
center, and informed consent was obtained from subjects
or their legal representatives.
COX7B (RefSeq accession number NM_001866.2) is
localized to the Xq21.1 region, comprises three coding
exons, and encodes an 80 amino acid mitochondrial
protein. Using specific primers listed in Table S1 (available
online), we sequenced the coding region and exon-intron
boundaries of COX7B in the above-described cases. In case
1, this analysis led to the identification of a heterozygous
1 bp deletion, c.196delC (leading to a frameshift), in
exon 3 of COX7B (Figure 2A). This mutation most likelyer 2, 2012
Table 1. Clinical Features Reported inMLS-Affected Individuals Carrying Deletions or PointMutations inHCCS or PointMutations in COX7B
HCCS Deletions or Point Mutationsa COX7B Point Mutations
Occurrence Case 1 Case 2
Family 1
Clinical Features II.4 I.2
Microphthalmia 43/55 (78%)    
Sclerocornea 22/55 (40%)    
Other eye abnormalities 28/55 (51%)   þb 
Linear skin lesions 42/55 (76%) þ þ þ þ
Nail dystrophy 3/55 (5%) þ   
Microcephaly, agenesis of the corpus
callosum, and other CNS abnormalities
24/52 (43%) þ þ þ 
Intellectual disability 9/42 (21%)  þ þ 
Short stature 16/36 (44%) þ þ  
Cardiac abnormalities 21/52 (40%)  þ þ 
Diaphragmatic hernia 3/55 (5%)  þ  
Genitourinary abnormalities 14/55 (25%)  þ  
Please note that for each feature listed in the table, the total number of individuals taken into account includes only cases in whom each clinical feature was
analyzed and documented.
aSee GeneReviews in Web Resources, as well as Sharma et al.,8 Kono et al.,26 and Zumwalt et al.27
bPale optic discs and altered visual-evoked potentials.leads to the generation of a COOH-terminal truncated
COX7B with 46 novel amino acids (p.Leu66Cysfs*48).
The resulting mutant protein is predicted to lack the
domain that interacts with the two COX subunits, namely
COX4 and COX6C.22 The mutation was absent in the
parents (paternity confirmed) and in 200 ethnically
matched controls (data not shown).
In case 2, COX7B sequence analysis revealed the pres-
ence of a heterozygous splice mutation (c.41-2A>G) in
intron 1 (Figure 2B). The mutation was absent in the
parents. This mutation is predicted to create in intron 1
a novel splice acceptor site one base before the wild-type
(WT) splice site. In vitro analysis of the c.41-2A>G change
was performed by the Exon Trapping System (GIBCO
Invitrogen). A 2,705 bp genomic fragment that encom-
passes intron 1, exon 2, and intron 2 of COX7B for both
WT and mutant sequences was cloned into vector pSPL3,
sequenced for integrity, and transfected into COS-7 cells.
We analyzed ten WT (c.41-2A) and ten mutant (c.41-2G)
COX7B transcripts. In all transcripts obtained from the
WTminigene, we identified a normal sequence (Figure 2D).
In contrast, 90% of the mutated transcripts contained
an additional guanine at the beginning of exon 2; this
addition led to out-of-frame transcripts and most likely
to the formation of a truncated COX7B with 18 novel
amino acids at the COOH-terminal region (p.Val14Glyfs*
19) (Figure 2D).
Finally, we also identified a heterozygous nonsense
mutation (c.55C>T [p.Gln19*]) in the second exon of
COX7B in individual II.4 (Figure 2C). The mutation was
identified in both individual II.4 and her mother (I.2),
whereas the three healthy sisters (II.1, II.2, and II.3) ofThe Americanindividual II.4 and her healthy brother (II.5) inherited
the WT COX7B allele from their mother (Figure 1C). This
mutation might result either in a functional null allele as
a result of nonsense-mediated mRNA decay (NMD) or
in a COX7B lacking a large COOH-terminal portion
(Daa19–80). The latter assumption is more likely given
that mRNAs with a premature termination codon located
within 50–55 nt upstream of the most 30 exon-exon junc-
tion are generally not targeted for NMD.25
None of the nucleotide changes were present in the
available databases (dbSNP or the National Heart, Lung,
and Blood Institute [NHLBI] Exome Variant Server). All
together, our results clearly indicate that mutations in
COX7B cause MLS. Table 1 illustrates the clinical features
observed in individuals with deletions or point mutations
in HCCS and those observed in individuals with point
mutations in COX7B. Some of the individuals in whom
no mutation in either COX7B or HCCS could be identified
might bear small deletions not identified in the present
study. It is also possible that mutations in other MRC-
associated genes will possibly explain these cases.
The function of COX7B within CIV is still unknown. To
investigate this issue, we silenced COX7B in HeLa cells
by using ON-TARGET siRNA (Dharmacon) against
human COX7B and ON-TARGET Non-Targeting siRNA
(Dharmacon) to a final concentration of 50 nM. Measured
by quantitative real-time PCR, the degree of COX7B
silencing in siRNA-treated HeLa cells (HeLaCOX7B) was
>50% higher than the levels detected in HeLa cells
incubated only with the transfection reagent (HeLaWT)
and HeLa cells transfected with nontargeting siRNA
(HeLaC) (Figure S1).Journal of Human Genetics 91, 942–949, November 2, 2012 945
Figure 3. COX7B Is Necessary for CIV Activity, Assembly, and MRC Functioning
(A) COX histochemical reactions in HeLaWT, HeLaC, and HeLaCOX7B cells; note the marked reduction in HeLaCOX7B cells compared to
controls. The bottom panel shows the number of COX-positive cells in each sample.
(B) In-gel activity of CIV on 1D-BNGE in the same cells. 1D-BNGE was performed on mitochondria isolated from HeLa cells as
described.29 COX-specific in-gel activity was visualized on 100 mg of protein (for each sample) run through 1D-BNGE as described.30
The intensity of the COX-specific band was markedly reduced in HeLaCOX7B lysate.
(C) 1D-BNGE immunoblot analysis of mitochondria immune visualized with antibodies against COI and against the 70 kDa (SDHA) CII
subunit used as a control.
(D) Immunodetection of CIVassembly intermediates on two-dimensional BNGE immunoblot showsmarked decrease in the steady-state
level of CIV holoenzyme detected by the COI antibody in HeLaCOX7B cells. The amount of loaded samples is the same as in (C).
(E) The OCR was measured by microscale oxygraphy in different conditions as described in Invernizzi et al.31 The resulting OCR profile
in HeLaWT, HeLaCOX7B, and HeLaC cells was normalized to cell number.
(F) Analysis of the MRR in HeLaWT, HeLaCOX7B, and HeLaC cells. MRR was calculated by the subtraction of the rotenone-insensitive
OCR from OCR-F (OCR after FCCP addition). Error bars represent the standard deviation; *p < 0.05, **p < 0.01, ***p < 0.001 in an
unpaired, two-tailed Student’s t test.We first carried out a COX-specific histochemical reac-
tion28 that showed markedly reduced signal in HeLaCOX7B
cells compared to bothHeLaWTandHeLaC cells (Figure 3A).
We then measured in-gel COX activity on mitochondrial
extracts fromHeLaWT, HeLaC, andHeLaCOX7B cells (extracts
were separated by one-dimensional blue-native gel elec-
trophoresis [1D-BNGE]). The COX-specific reactive band
was markedly reduced in the HeLaCOX7B extract, in striking
contrast with the robust reaction detected in both HeLaWT
and HeLaC extracts (Figure 3B). Holo-COX immuno-
detection by immunoblot analysis on 1D-BNGE with anti-
COX subunit I (COI) antibodies showed marked reduction
of the fully assembled COX inHeLaCOX7B cells as compared
toHeLaWTandHeLaC samples (Figure 3C). Likewise, immu-
noblot analysis on two-dimensional BNGE showed that
COI cross-reacting material was present at the position
corresponding to the fully assembled COX in HeLaWT946 The American Journal of Human Genetics 91, 942–949, Novemband HeLaC samples, whereas it was hardly detectable
in HeLaCOX7B samples insomuch that it prevented the
visualization of any possible subassembly intermediate
(Figure 3D).
We also analyzed the oxygen-consumption rate (OCR)
in living cells by using microscale oxygraphy (XF96
Seahorse) according to described protocols.31 The OCR
was measured in basal conditions (OCR-B) in the presence
of the CV inhibitor oligomycin (OCR-O), corresponding to
respiration state 4, and in the presence of the OXPHOS
uncoupler FCCP (OCR-F), corresponding to respiration
state 3.31,32 Values were significantly lower in HeLaCOX7B
cells than inHeLaWTandHeLaC cells (Figure 3E); as a conse-
quence, the maximal respiration rate (MRR), an index of
the functional reserve of mitochondrial respiration that
is obtained by the subtraction of OCR-B from OCR-F,31,32
was also reduced (Figure 3F). These results demonstrateer 2, 2012
Figure 4. cox7B Downregulation In Vivo
Mimics MLS
Bright-field dorsal views of embryos in-
jected with a control MO (A), cox7B MO
(B), cox7B MO þ hCOX7B mRNA (C),
cox7B MO þ c.196delC-hCOX7B mRNA
(D) at stage 38. The injection of the cox7B
MO induced microphthalmia (vertical
dashed line in B) and microcephaly (hori-
zontal dashed line in B). The overexpres-
sion of hCOX7B mRNA fully rescued mi-
crophthalmia and microcephaly (vertical
and horizontal dashed lines in C), induced
by MOs showing the specificity of the morphant phenotype. No amelioration of the phenotype was observed in embryos coinjected
with cox7B MO þ c.196delC-hCOX7B mRNA, indicating that this mutation impairs COX7B activity (D). Scale bars represent 100 mm.
MOs (Gene Tools) were injected into fertilized embryos at the 1- to 2-cell stage. mRNA sequences corresponding to WT hCOX7B
and c.196delC hCOX7B were obtained with the SP6 mMessage mMachine kit (Ambion). Rescue experiments were performed by
coinjection of WT hCOX7B and c.196delC hCOX7B with the cox7B MO into one blastomere of the embryos at the 1- to 2-cell stage.
eGFP mRNA was always included in the injection solutions as a reporter.that the COX7B subunit is necessary for COX activity,
COX assembly, and mitochondrial respiration.
Finally, to evaluate the role of COX7B in vivo, we down-
regulated cox7B in medakafish (Oryzias latipes) by using
a morpholino (MO)-based knockdown approach. We iden-
tified the medaka COX7B ortholog (cox7B) by screening
available genomic sequences by using the human and
murine COX7B sequences (RefSeq NP_001857.1 and
NP_079655.1, respectively). The entire cox7B coding
sequence, including part of the 50 UTR, was isolated
by reverse-transcriptase-PCR amplification from cDNA
derived from a pool of medaka embryos at different
stages (data not shown). The medaka cox7B transcript
(HE717026) encodes a 78 amino acid protein with 51%
identity to the human COX7B. We designed a specific
MO against the second splice acceptor site (cox7B MO)
and injected it into embryos at the 1- to 2-cell stage.
Embryos injected with a mutated form of the MO (control
MO) were used as controls. The efficiency and specificity of
MOs (Gene Tools) were verified with the recommended
controls33 (Figure S2 and Tables S1 and S2).
The cox7Bmorphants showed a dose-dependent pheno-
type characterized by microcephaly and microphthalmia
(Figures 4A and 4B and Table S2). The presence of micro-
phthalmia after cox7B downregulation demonstrates that
COX7B plays a role in eye development. Therefore, the
lack of microphthalmia in the cases analyzed (Table 1)
might be explained by a selective pattern of X inactivation
in those individuals.11,12 The identification of additional
cases with COX7B mutations will be crucial for clarifying
this issue. Morphant embryos also displayed cardiovas-
cular abnormalities with evident pericardial edema and
formation of an unlooped heart (Figure S3). Interestingly,
two of the cases with COX7B point mutations presented
with cardiac abnormalities. These defects, which are
similar to those observed in hccs morphants (B.F., unpub-
lished data), were progressive and led to death at the
hatching stage. Injection of morphants with human (h)
COX7BmRNA rescued the phenotype (Figure 4C and Table
S2), demonstrating that COX7B function is important forThe Americanproper development and is conserved among vertebrates.
On the contrary, injection of c.196delC hCOX7B did not
rescue the phenotype, indicating that this mutation
impairs COX7B activity (Figure 4D and Table S2).
In summary, our results indicate that severe impairment
of the MRC’s terminal segment, which funnels all the
reducing equivalents from both NADHþHþ and FADH2
electron donors to O2, causes a severe developmental
phenotype, which is an uncommon feature in canonical
mitochondrial disorders. Interestingly, mutations in
nuclear-encoded subunits of CIII–CIV are exceptionally
rare in humans. To date, a single homozygous missense
mutation in the nuclear COX6B1 (MIM 124089), encoding
a COX subunit, has been reported in an individual with
mitochondrial encephalomyopathy (COX deficiency
[MIM 220110]).34
HCCS and COX7B are both ubiquitously expressed (data
available at BIOGPS database) given that they are required
for cellular respiration. However, the phenotypic manifes-
tations observed in MLS-affected females mainly affect the
CNS and other specific organs, suggesting that dosage and
function of these proteins are critical for selected tissues. It
is possible that differential tissue sensitivity to mitochon-
drial ATP depletion (high versus low energy demand)
and/or overproduction of reactive oxygen species might
elicit different molecular responses in the absence of
HCCS or COX7B in selected tissue types and might there-
fore induce the blockage of cell replication and/or an
increased cell death.1,35,36
Deregulation in these processes andX chromosome inac-
tivation could concur to select OXPHOS-proficient cells in
HCCS- and COX7B-depleted tissues, thus attenuating or
abolishing MRC defects in the surviving tissues and indi-
viduals. BothHCCS andCOX7B are subjected to X inactiva-
tion. Interestingly, X-linked genes show variable patterns
of inactivation and are expressed to different extents
from some inactive X chromosomes, suggesting a remark-
able degree of expression heterogeneity among females.37
The molecular basis of many inherited developmen-
tal disorders that involve the CNS still remains to beJournal of Human Genetics 91, 942–949, November 2, 2012 947
determined. On the basis of our results, MRC-related genes
might very well underlie lethal and so far unrecognized
developmental disorders and should be considered as
possible candidates for these conditions.
All together, our results indicate an essential role for
MRC function in correct CNS development and uncover
the existence of a group of mitochondrial diseases in
which impairment of the CIII–CIV MRC segment results
in developmental defects.Supplemental Data
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